



RRPV Member Spotlight: PharmaJet



Q: What does your company do? What specific capabilities or strengths does your company offer?

A: PharmaJet® is a global, innovative drug/device company that designs, develops and commercializes needle-free jet injection technologies to improve delivery of vaccines and therapeutics. PharmaJet's mission is to enable greater access to life improving medicines and is committed to helping its partners realize their research, development, and commercialization goals, while serving patients with a preferred injection experience. PharmaJet's Needle-free Injection Systems aim to improve outcomes.

PharmaJet needle-free delivery systems are:

- Designed for multiple uses in the field
- Lower per unit cost compared to one-time use autoinjector combination products
- Sustainable - less waste per treatment (syringe only)
- Compatible with current U.S. supply chain and PoC distribution
- Designed for standard vial dosing (requires less training)
- Potentially offers a streamlined regulatory path to FDA clearance
- Manufactured at commercial scale and quality
- Platform technologies that can be adapted to BARDA

Q: Are there any specific partnership opportunities you're seeking with other members in the industry? What kinds of expertise or resources would be beneficial for your company to explore through partnerships?

A:

- Seeking to partner our needle-free technology with manufacturers' products
- Clinical Arm Trial (Oncology, Auto-Immune, and Vaccines)
- Early-stage development product partnership
- Pandemic partnership, at home use



- Emergency personnel chemical protection
- CEPI Disease X development

Q: Provide some insight about your company's history, core business areas, focuses, or key ideas that you wish to describe.

A: We offer these benefits with our needle free Intradermal technology over needles and syringes:

- Benefits of Intradermal compared to IM delivery
- Longer duration of the antibody response
- Mucosal Immunity
- Cross-reactive antibody and T cell responses

Q: What trends or innovations do you foresee shaping the future of the industry, and how is your company preparing for those changes?

A:

- Simplified way to give medications, at home and faster with no needle
- Ease of administration (potential for home use)
- Disposable syringe (vs. entire autoinjector)
- Rapid Administration - 0.1 seconds
- No drug reformulation required
- Designed and validated for 20,000 uses per injector
- Improved patient acceptability (vs. needles)
- Platform proven compatible with various products and technologies

Q: How can we contact you?

Thomas Hess: Senior Director, Corporate Development
tom.hess@pharmajet.com

Dan Mallon: Vice President, Corporate Development
dan.mallon@pharmajet.com